TSHA earnings date and last-quarter result: last quarter beat, P/E -14.79. Updated 2026-07-23.
Taysha Gene Therapies (TSHA) Research Hub
Taysha Gene Therapies (TSHA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.01 USD (+1.26%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.79, market cap 1.40B. This hub links to the full technical, earnings and options research available for TSHA.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.01 USD (+1.26%) |
| 52-week range | 3.455 USD – 7.12 USD |
| Trend regime | Range |
| 14-day RSI | 41 (Bearish) |
| Trailing P/E | -14.79 |
| Market cap | 1.40B |
| Dividend yield | 0.00% |
Available research for TSHA
Covered Call on TSHA: how it works, illustrative setup around the real 4.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TSHA: how it works, illustrative setup around the real 4.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TSHA: how it works, illustrative setup around the real 4.01 USD price, max profit/loss, breakeven and when to use it. Educational.
TSHA technical analysis: range, last 4.01 USD, RSI 41, 52w range 3.455 USD–7.12 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is TSHA in?
Taysha Gene Therapies (TSHA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TSHA in an uptrend or downtrend?
As of 2026-10-26, TSHA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TSHA's trailing P/E ratio?
TSHA's trailing P/E is -14.79, with a market cap of 1.40B. See the earnings research page for full valuation detail.